Related Experiment Videos
Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease
Harry J Linton1, Leonard S Marks, Lisa S Millar
1Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc., 7330 Carroll Road, San Diego, CA 92121, USA.
Clinical Chemistry
|February 1, 2003
Summary
Benign prostate-specific antigen (BPSA) is a significant part of free PSA in men with benign prostatic hyperplasia (BPH). This new immunoassay can measure BPSA, potentially aiding BPH diagnosis.
Area of Science:
- Biochemistry
- Immunology
- Urology
Background:
- Benign prostate-specific antigen (BPSA) is elevated in prostate tissues of men with benign prostatic hyperplasia (BPH).
- BPSA is a specific form of free prostate-specific antigen (PSA).
- An immunoassay was developed to quantify BPSA in serum.
Purpose of the Study:
- To develop and validate a highly specific immunoassay for BPSA.
- To determine the concentration and proportion of BPSA in the serum of men with BPH.
Main Methods:
- Purification of BPSA antigen using HPLC.
- Development of murine monoclonal antibodies against BPSA.
- Creation of a fluorogenic ELISA with high specificity for BPSA.
Main Results:
- The immunoassay demonstrated high specificity for BPSA with <1% cross-reactivity.
- BPSA constituted a median of 25% of free PSA in men with BPH and in prostate cancer patients.
- BPSA was undetectable in control serum from women or men without elevated PSA.
Conclusions:
- BPSA represents a significant fraction of free PSA in BPH patients' serum.
- Prostate cancer does not significantly alter BPSA proportions in sera with low total PSA.
- BPSA measurements may offer valuable clinical insights for BPH research and management.